Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Stephens & Co. Downgrades FB Financial to Equal-Weight

Stephens & Co. analyst Matt Olney downgrades FB Financial (NYSE:FBK) from Overweight to Equal-Weight.

byBenzinga Newsdesk

December 13, 2022

1 minute read

Stephens & Co. analyst Matt Olney downgrades FB Financial (NYSE:FBK) from Overweight to Equal-Weight.

SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 4:48 AM

SVB Leerink analyst Mani Foroohar maintains AlloVir (NASDAQ:ALVR) with a Outperform and lowers the price target from $32 to $30.

ALVR

Events
News

Pfizer To Host Webcast At Cantor’s Global Healthcare Conference Monday, Sept. 27, 2021 At 12:10 p.m. EDT

By Benzinga Newsdesk

Today, 4:48 AM

Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the Cantor Global Healthcare Conference on Monday, September 27, 2021 at

PFE

Oppenheimer Maintains Outperform on Coinbase Glb, Lowers Price Target to $70

By Benzinga Newsdesk

Today, 4:48 AM

Oppenheimer analyst Owen Lau maintains Coinbase Glb (NASDAQ:COIN) with a Outperform and lowers the price target from $84 to $70.

COIN

Analyst Ratings

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals

By Benzinga Insights

Today, 4:48 AM

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:

APLS

Stephens & Co. Downgrades FB Financial to Equal-Weight

Related Posts

SVB Leerink Maintains Outperform on AlloVir, Lowers Price Target to $30

Pfizer To Host Webcast At Cantor’s Global Healthcare Conference Monday, Sept. 27, 2021 At 12:10 p.m. EDT

Oppenheimer Maintains Outperform on Coinbase Glb, Lowers Price Target to $70

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals